Drug General Information (ID: DDI72X4VLP)
  Drug Name Trandolapril Drug Info Monopotassium phosphate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Minerals And Electrolytes
  Structure

 Mechanism of Trandolapril-Monopotassium phosphate Interaction (Severity Level: Major)
     Increased risk of hyperkalemia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Trandolapril Monopotassium phosphate
      Mechanism Hyperkalemia Hyperkalemia
      Key Mechanism Factor 1
Factor Name Hyperkalemia
Factor Description Hyperkalemia is a condition in which the level of potassium in the blood is higher than normal. While mild cases may not produce symptoms, severe hyperkalemia can lead to fatal arrhythmias if left untreated.
      Mechanism Description
  • Increased risk of hyperkalemia by the combination of Trandolapril and Monopotassium phosphate 

Recommended Action
      Management Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.

References
1 Warren SE, O'Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2. [PMID: 7001073]
2 Chan TY, Critchley JA "Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements." Drug Saf 7 (1992): 159-61. [PMID: 1605901]
3 Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.